AOD-9604 (5mg)

AOD-9604 Peptide (5 mg) – Product Description

AOD-9604 is a high-purity research peptide derived from the C-terminal fragment of human growth hormone (hGH 176–191). It is engineered for controlled laboratory investigation of lipid metabolism, energy expenditure pathways, and adipose tissue signaling. Each vial of AOD-9604 is synthesized to research-grade standards and undergoes rigorous analytical testing to support reproducible, protocol-driven experimental design.

AOD-9604 Research Peptide Specifications:

What Is AOD-9604? Research Background and Mechanism

AOD-9604 is a synthetic peptide fragment corresponding to the 176–191 region of human growth hormone, extended with an N-terminal tyrosine. Preclinical models indicate that this fragment retains the lipolytic and anti-lipogenic signaling properties of native hGH while minimizing broader growth hormone–related effects.

In animal studies, AOD-9604 has been investigated for its impact on adipocyte lipid turnover, beta-adrenergic receptor expression, and energy expenditure. Chronic administration in obese mouse models has been associated with changes in body weight, fat mass, and β₃-adrenergic receptor mRNA expression, supporting its use as a tool compound for dissecting adipose tissue signaling networks.

Beyond direct effects on adipocytes, AOD-9604 has been evaluated in toxicology and pharmacokinetic studies across multiple species, including rodents, pigs, and non-human primates. These studies provide insight into systemic distribution, rapid peptide degradation, and oral versus parenteral exposure profiles, and are frequently referenced when designing contemporary preclinical research protocols.

Importantly, while AOD-9604 has been studied in the context of obesity and metabolic health, it is not approved by the U.S. Food and Drug Administration (FDA) for weight loss or any therapeutic indication. Regulatory agencies have emphasized that AOD-9604 remains an investigational compound, reinforcing its role as a research-only peptide.

Important Research Notice: Nordsci peptides are supported by independent third-party analytical testing to validate identity and purity via HPLC and mass spectrometry. A Certificate of Analysis (COA) is available for each lot to help labs align with internal quality management and documentation requirements.

THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.

AOD-9604 Peptide Research: Key Laboratory Applications

1. Lipid Metabolism and Adipose Tissue Research

Preclinical studies have shown that AOD-9604 can modulate lipid metabolism in obese mouse models, including effects on body fat, lipolysis, and beta-adrenergic signaling. In one frequently cited study, chronic AOD-9604 administration altered β₃-adrenergic receptor expression in adipose tissue, providing a mechanistic framework for exploring adipocyte responsiveness and energy mobilization in obesity research.

These findings position AOD-9604 as a useful probe for investigating the interface between growth hormone fragments, adrenergic pathways, and downstream lipid handling across different fat depots.

2. Energy Expenditure and Obesity Models

AOD-9604 has been evaluated in models that track changes in energy expenditure, substrate utilization, and thermogenesis. Data from obese and β₃-adrenergic receptor knockout mice suggest that the peptide can influence energy expenditure and fat oxidation independently of direct β₃-receptor agonism, making it a candidate for studying non-classical pathways of metabolic activation.

Researchers frequently integrate AOD-9604 into broader metabolic protocols that measure body mass, indirect calorimetry endpoints, and transcriptional changes in key metabolic tissues.

3. Safety, Toxicology, and Pharmacokinetics

Comprehensive toxicology programs have investigated AOD-9604 across rats, pigs, and non-human primates, examining clinical chemistry, organ histopathology, and potential mutagenicity endpoints. Long-term dosing studies (up to several months) have reported rapid plasma clearance, high first-pass metabolism, and limited accumulation, with no major toxicological red flags at tested research doses.

These datasets are frequently used to design new animal protocols, particularly when researchers seek to understand exposure–response relationships, peptide degradation kinetics, or tissue distribution patterns relevant to metabolic and endocrine research.

4. Combination and Stack-Based Metabolic Research

Within experimental frameworks, AOD-9604 is sometimes studied alongside other metabolic peptides or small molecules to evaluate potential synergy or pathway complementarity. In these models, investigators typically focus on endpoints such as adipocyte turnover, hepatic lipid handling, and endocrine markers that collectively define the metabolic phenotype.

All such applications remain strictly preclinical. Any discussion of “weight loss” in the literature refers to animal and in vitro research endpoints, not validated clinical outcomes in humans.

AOD-9604 Research Protocol and Reconstitution

Reconstitution Guidelines for Laboratory Use:

For laboratory work, each 5 mg vial of AOD-9604 is typically reconstituted with 1–2 mL of bacteriostatic water or another suitable sterile diluent to achieve the desired stock concentration. The precise concentration, route, and schedule should be determined by the research team in accordance with study design, species, and institutional standards.

Protocol Design Considerations: Published animal studies have utilized a range of exposure durations, dosing frequencies, and administration routes (including oral and parenteral delivery) when characterizing AOD-9604. Researchers should rely on peer-reviewed literature, local regulatory guidance, and IACUC/ethics committee approvals when translating these frameworks into new protocols.

Note: The information above is provided as a high-level research reference only. All experimental use must be conducted by qualified personnel in appropriately equipped facilities, following applicable regulations and institutional animal care and use policies.

AOD-9604 Certificate of Analysis (COA) – Lab Testing

Each lot of AOD-9604 is supported by a detailed Certificate of Analysis documenting peptide identity, purity, and analytical methods used (HPLC, mass spectrometry, and related assays as applicable). COA documentation is supplied with qualifying orders and can be obtained from Nordsci customer support for protocol files, regulatory submissions, or internal quality audits.

Where to Buy AOD-9604 for Research Purposes

Sourcing AOD-9604 for institutional use requires partnering with suppliers that maintain robust quality systems and transparent analytical documentation. Nordsci Peptides focuses on providing high-purity, research-grade peptides with consistent lot-to-lot performance and clear labeling for laboratory applications.

How to Source AOD-9604 for Laboratory Research

When selecting a supplier, laboratories should verify that each batch of AOD-9604 includes clear labeling, batch/lot identifiers, COA access, and validated purity data. This level of documentation helps research teams align with internal SOPs, GLP-style practices, and ethics or compliance committee expectations.

AOD-9604 Research Peptide Pricing Considerations

Research-grade AOD-9604 pricing is typically driven by unit size, synthesis complexity, purity targets, and the depth of analytical testing performed. Many institutions account not only for per-milligram cost, but also for the compliance value of strong documentation and stable supply when budgeting for multi-phase or multi-cohort studies.

Research Institution Procurement and Compliance

Procurement teams should ensure that AOD-9604 is purchased exclusively for non-clinical use under documented research protocols. Storage, handling, and inventory records should be maintained in alignment with internal quality procedures to support data integrity and regulatory readiness.

IMPORTANT: AOD-9604 is sold exclusively for in vitro and preclinical research applications. It is not approved for human use, weight-loss treatment, or any therapeutic purpose. Researchers are responsible for complying with all applicable regulations and institutional policies governing peptide research in their jurisdiction.